Search Browse Earnings

Monte Rosa Therapeutics, Inc. — SlamSEC

Monte Rosa Therapeutics, Inc.

Nasdaq:GLUE

Biological Products, (No Diagnostic Substances)·BOSTON, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$0

FY 2024

Adj. EBITDA

-$137.1M

FY 2024

Net Income

-$135.4M

FY 2024

EPS (Diluted)

—

Stock Price

$16.03

-6.0%

2026-03-13

52W Range

$3.50 – $25.77

P/E Ratio

—

Market Cap

$1.0B

Cash

$128.1M

FY 2024

Total Debt

—

Net Cash

$128.1M

FY 2024

Enterprise Value

$915.7M

Debt / EBITDA

0.9x

FY 2024

EV / EBITDA

-6.7x

Employees

—